BioCentury
ARTICLE | Clinical News

Vargatef nintedanib: Completed Phase III enrollment

October 1, 2012 7:00 AM UTC

Boehringer completed enrollment in the identical, double-blind, placebo-controlled, international Phase III INPULSIS-1 and INPULSIS-2 trials evaluating 150 mg oral nintedanib twice daily over 52 weeks...